

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/062219 A1

(51) International Patent Classification⁷: C07D 333/20

MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US03/00018

(22) International Filing Date: 13 January 2003 (13.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/351,622 24 January 2002 (24.01.2002) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BORGHESE, Alfio** [IT/BE]; Lilly MSG Development Centre S. A., Parc Scientifique de Louvain-la-Neuve, B-1348 Mont-Sai Rue Granbompre', 11 (BE).

(74) Agents: **ANDERSON, Arvie, J. et al.**; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARING AN INTERMEDIATE USEFUL FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE

(57) Abstract: This invention provides a process for the synthesis of (S)-3-Methylamino-1-2-thienyl)-1-propanol, a key intermediate in the synthesis of duloxetine.

WO 03/062219 A1

PROCESS FOR PREPARING AN INTERMEDIATE USEFUL FOR THE ASYMMETRIC SYNTHESIS OF DULOXETINE


BACKGROUND OF THE INVENTION


5 This invention belongs to the fields of pharmaceutical chemistry and synthetic organic chemistry, and provides a process for the synthesis of a key intermediate in the preparation of duloxetine, (+) N-methyl-3(1-naphthalenyloxy)-3-(2-thienyl)propanamine, hydrochloric acid salt.

Duloxetine is a pharmaceutical now under development as an anti-depressant. It 10 inhibits the uptake of both norepinephrine and serotonin and is presently in clinical evaluation. The compound was disclosed in U.S. Pat. Nos. 5,023,269 and 4,956,388 by Robertson, et al. and the synthesis of it was discussed in more detail by Berglund, R.A., *Org. Proc. Res. Devel.*, 1, 328 (1997) and Deeter, et al., In *Tetrahedron Letters*, 31(40), 7101-04 (1990) and aspects patented in U.S. Patent Nos. 5,362,886 and 5,491,243.

15 Synthetic schemes and processes have been reported for conversion to duloxetine. Two particular reported synthetic schemes in Liu, H.; Hoff, B.H.; Authonsen, T. *Chirality*, 12, 26 (2000) and Wheeler, W.J.; Kuo, F.S. *Labelled Compd. Radiopharm.*, 36, 213 (1995), have a common chloroalcohol intermediate. In both cases this chloroalcohol intermediate is converted to an aminoalcohol, in two steps and then arylated to give 20 duloxetine. These processes, as reported in the above articles, are outlined in Schemes 1 and 2.

Scheme 1



Scheme 2

Although the arylation of (S)-3-Methylamino-1-(2-thienyl)-1-propanol, compound I in Schemes 1 and 2, has been disclosed, its resolution via diastereomeric salt formation has not been shown. Further, while Racemic ((R/S)-3-Methylamino-1-(2-thienyl))-1-propanol has been disclosed in Bopp, R.J.; Kennedy, J. H., LC-GC, 5, 514 (1998), the resolution of this key intermediate has not been successful.

The present invention provides improved conditions for carrying out the resolution of ((R/S)-3-Methylamino-1-(2-thienyl))-1-propanol whereby resolved compound I is obtained in greater enantiomeric purity and yield than has previously been possible.

SUMMARY OF THE INVENTION

The present invention provides a process for preparing (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)-propanamine comprising resolving racemic ((S)-3-Methylamino-1-(2-thienyl))-1-propanol with 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid or S-(-)-2-pyrrolidone-5-carboxylic acid in a first organic solvent, and if desired, racemizing a stereomerically enriched mixture in an isopropanol/hydrochloric acid mixture; and if desired, crystallizing (S)-3-Methylamino-1-(2-thienyl)-1-propanol by resolving racemic ((R/S)-3-Methylamino-1-(2-thienyl))-1-propanol with 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid in a third organic solvent.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention provides a process for preparing the specific enantiomer shown above as compound I in Schemes 1 and 2 above. It is named (S)-3-Methylamino-1-(2-thienyl)-1-propanol.

The resolution step of the present invention is prepared by adding 1 molar equivalent of 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid or (S)-(-)-2-pyrrolidinone-5-carboxylic acid, preferably 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid, to racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol in an organic solvent at room temperature, yielding after crystallization a mixture of diastereomeric salts. The organic solvent may be, for example, isopropanol, tetrahydrofuran, acetone or ethyl acetate. Isopropanol is the preferred solvent. If the resolution is performed as part of a process which later involves crystallization of (S)-3-methylamino-1-(2-thienyl)-1-propanol, the above solvent is a first organic solvent. Diastereomerically enriched crystals are obtained by additional crystallizations. Example 1, below, illustrates this procedure in detail. Chiral analysis was done by capillary electrophoresis(ce) and the results summarized in Table 1 below.

Table 1

Optical resolution and purification of racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol in isopropanol.

| | Crystals Enantiomeric Composition (%area/%area) | ML Enantiomeric Composition (%area/%area) | Cryst. Yield (%) | ML Yield (%) |
|------------------------------------|--|---|------------------------|-----------------|
| Optical resolution | 56/44 | 25/75 | 74 | 23 |
| 2 nd optical purify. | 62/38 | 28/74 | 79 | 19 |
| 3 rd optical purif. | 89/11 | 26/74 | 58 | 38 |

ML= mother liquor

The enriched diastereomer salts (diastereomeric excess (d.e.) = 78%) were obtained with 33 % overall yield. The optical resolution of (S)-3-Methylamino-1-(2-thienyl)-1-propanol (d.e. = 78%) measured in methanol is $[\alpha]_D^{25} = -9.6$ (MeOH, C = 4.4). The sign and the value of this optical rotation compared with the literature value $[\alpha]_D^{25} = -12.5$ (MeOH, C = 4.4), Huiling Liu, Bard, Helge, Hoff and Thorleif Authorsen, *Chirality*, 12, 26-29 (2000) of the (S) enantiomer demonstrates that the wanted stereomer is obtained with the resolving agent 2,3,4,6-di-O-isopropylidene-2-keto-(gulonic acid with an optical

purity of 76.8%. Additional crystallization steps would be necessary to obtain optical pure (S)-3-methylamino-1-(2-thienyl)-1-propanyl.

The racemization step of (S)-3-Methylamino-1-(2-thienyl)-1-propanol is achieved by partially racemizing a stereomerically enriched mixture (d.e. = 76%) of (S)-3-Methylamino-1-(2-thienyl)-1-propanol (as a salt form with 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid) in isopropanol/hydrochloric acid mixture at room temperature as shown in Example 2 below. This process or another acid catalysis can be used to recycle the mixture of salts of (S)-3-Methylamino-di-O-isopropylidene-2-keto-L-gulonic acid enriched in the unwanted stereoisomer.

Finally a second order asymmetric induced crystallization was achieved by performing the optical resolution of racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol with 1 equivalent of 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid in an organic solvent such as isopropanol, tetrahydrofuran, acetone or ethyl acetate, preferably isopropanol, at 40°C, and the reaction mixture left agitated at that temperature for 66 hours. If the crystallization is performed after the resolution step described above, the organic solvent used in the crystallization step is a second organic solvent. An example is provided below. The diastereomeric crystals were obtained with a yield of 76% (diastereomeric composition (-)/(+) = 88%/12%); (M.L.: yield = 18%, d.e. = 50%, (diastereomeric composition (-)/(+) = 25%/75%)).

Analysis of the mass balance of each diastereomer (crystal + mother liquors), shows that a second order asymmetric induced crystallization occurred during this optical resolution process. These results show the formation of the desired diastereomer at the expense of the unwanted one.

Example 1

Optical Resolution

To the free base racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol (1 g) dissolved in isopropanol (45 ml) was added the 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid (1.634 g) at room temperature and stirred for 4 hours.

The resulting salt is filtrated and dried under reduced pressure at 40°C to yield 1.945 g. of a white solid (y = 74%, d.e. = 12%).

Optical purifications

The resulting solid of Example 1 (1.873 g, d.e. = 12%) is suspended in isopropanol (82 ml) and stirred at room temperature for 69 hours.

- 5 The suspension is filtrated, dried under vacuum at 40°C to yield 1.483 g of the diastereomeric salt (y = 79%, d.e. = 24%). The resulting solid (1.382 g, d.e. = 24%) is suspended in isopropanol (159 ml) and stirred at room temperature for 16 hours. The suspension is filtrated, dried under vacuum at 40°C to yield 0.803 g of the diastereomeric salt (y = 58%, d.e. = 78%)

10

Example 2Racemization procedure

- 15 To the diastereomeric salt (d.e. = 75%) suspended in isopropanol (1 ml) was added HCl 1N (216 L). At that time solubilization of the salt occurred. The reaction mixture was stirred for 2 hours 30 minutes and concentrated under vacuum. The resulting solid has a d.e. = 32% (CE analysis).

Example 320 Second order induced crystallization

- To the free base racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol (1 g) dissolved in isopropanol (31.3 ml) was added the 2,3,4,6-di-O-isopropylidene-2-keto-L-gulonic acid (1.634 g) at room temperature. The reaction mixture was heated to 40°C and stirred for 66 hours at that temperature. After cooling to room temperature, the solid was filtrated
25 and dried under reduced pressure at 40°C, to yield 1.993 g of a white solid (yield = 76%, d.e. = 76%).

- Analysis of the mass balance of each diastereomeric (crystal + mother liquors), shows that a second order asymmetric induced crystallization occurred during this optical resolution process. These results show the formation of the desired diastereomer at the
30 expense of the unwanted one.

The advantage of the present invention is found in its ability to prepare the desired product in high optical purity, with very little racemization, in short periods of time with resolution via diastereomeric salt formation as described above.


The synthesis of duloxetine is discussed in detail by Deeter, et al., in *Tetrahedron Letters*, 31(49), 7101-7104 (1990). Further synthetic Schemes 1 and 2 above, both of which are described in the prior art, provide enablement for making the racemic starting material for the current invention.

Briefly, as described in Scheme 2, the process described in Liu, H.; Hoff, B.H.; Anthonsen, T. *Chirality*, 12, 26 (2000), the (S)-chloroalcohol is derived from a Friedel-Crafts reaction of thiophene and 3-chloropropionyl chloride. The chloroketone was reduced and the racemic alcohol is resolved enzymatically with immobilized *Candida Antarctica* Lipase B to give (S)-chloroalcohol in 35% Yield (97% enantiomeric excess). See Liu et, al.


In Scheme 2 above, Wheeler, W.J.; Kuo, F.J. *Labelled Compound Radiopharm.*, 36, 213 (1995) took a longer route to prepare "C-labeled duloxetine." The chloroketone was reduced with a chiral borane reagent to give the (S)-chloroalcohol directly in 85% yield. Iodination and amination as before complete the synthesis of duloxetine.

A final route to either optically pure or racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol employs demethylation of the dimethylamino intermediate as shown below in Scheme 3 and 4. Precedent for the final route may be found in U.S. Patent No. 5,225,585.

Scheme 3




Scheme 4



In Scheme 3 above, the starting material 2-acetylthiophene is converted to the Mannich ketone as described in Blicke, F.F.; Berckhalter, S.H., *J. Amer. Chem. Soc.*, 64, 451 (1941). The ketone is reduced to give racemic amino alcohol as described in Valenta, V.; Vilková, M.; Valchár, M.; Dobrovsky, K.; Polivka, 7, *Collect Czech. Chem. Commun.* 1991, 56, 1525; Jakobsen, P.; Kanstrup, A.; Lundbeck, J.M., Eur. Pat. Appl. EP 571,685, 1993 and Klosa, J., *J. Prakt. Chem.*, 1966, 34, 312 (Path A). Alternatively, the Mannich ketone can be reduced with chiral reducing agent to give the chiral S-amino alcohol directly (Path B).

Demethylation of the dimethylamino intermediate may be achieved by, for example, protecting the alcohol as a carbonate and using additional chloroformate to demethylate intermediate C above in Scheme 4 by organic chemistry methods shown in the art.

While the racemic compound I shown below as disclosed in Bopp, R. J. Kennedy, J.H., LC-GC, 6, 514 (1988), the resolution of this key intermediate has not been accomplished. The present invention achieves this resolution with high optical purity.



WE CLAIM:

1. A process for preparing (S)-3-Methylamino-1-(2-thienyl)-1-propanol comprising:
5 resolving racemic – (S)-3-Methylamino-1-(2-thienyl)-1-propanol with (S)-(-)-2-pyrrolidone-5-carboxylic acid or 2,3,4,5-di-O-isopropylidene-2-keto-L-gulonic acid in a first organic solvent;
racemizing a stereomerically enriched mixture; and crystallizing (S)-3-Methylamino-1-(2-thienyl)-1-propanol by resolving racemic (S)-3-Methylamino-
10 1-(2-thienyl)-1-propanol with 2,3,4,6-di-O-isopropylidene in a second organic solvent.
2. The process of Claim 1 wherein the resolution of racemic (S)-3-Methylamino-1-(2-thienyl)-1-propanol is with 2,3,4,6-di-O-isopropylidene-2-keto-L-
15 gulonic acid.
3. The process of any one of Claims 1 or 2 wherein the first organic solvent is selected from isopropanol, tetrahydrofuran, acetone or ethyl acetate.
- 20 4. The process of any one of Claims 1, 2 or 3 wherein the first organic solvent is isopropanol.
5. The process of any one of Claims 1 through 4 wherein the second organic solvent is selected from isopropanol, tetrahydrofuran, acetone or ethyl acetate.
25
6. The process of any one of Claims 1 through 5 wherein the second organic solvent is isopropanol.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/00018

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D333/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | US 5 362 886 A (BERGLUND RICHARD A) 8 November 1994 (1994-11-08) column 3, line 59 -column 4, line 4 column 1-scheme-step B --- | 1-6 |
| Y | US 3 855 227 A (HOLLANDER C ET AL) 17 December 1974 (1974-12-17) column 1, line 40 -column 3, line 50; examples 2,3,9 --- | 1-6 |
| Y | US 4 036 852 A (BOESTEN WILHELMUS H J) 19 July 1977 (1977-07-19) claims; examples 3,5,7 --- | 1-6 |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

25 March 2003

Date of mailing of the international search report

02/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gavriliu, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/00018

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US 5 023 569 A (RAVEN GREGORY S) 11 June 1991 (1991-06-11) cited in the application column 2, line 44-57 column 4, line 59 -column 6, line 12 ----- | 1-6 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/00018

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| US 5362886 | A | 08-11-1994 | AT 199084 T | 15-02-2001 |
| | | | AU 685494 B2 | 22-01-1998 |
| | | | AU 7572094 A | 04-05-1995 |
| | | | BR 9404045 A | 13-06-1995 |
| | | | CA 2133899 A1 | 13-04-1995 |
| | | | CN 1109470 A , B | 04-10-1995 |
| | | | CZ 9402465 A3 | 17-05-1995 |
| | | | DE 69426663 D1 | 15-03-2001 |
| | | | DE 69426663 T2 | 21-06-2001 |
| | | | DK 650965 T3 | 26-02-2001 |
| | | | EP 0650965 A1 | 03-05-1995 |
| | | | ES 2153850 T3 | 16-03-2001 |
| | | | FI 944773 A | 13-04-1995 |
| | | | GR 3035715 T3 | 31-07-2001 |
| | | | HU 68943 A2 | 28-08-1995 |
| | | | IL 111188 A | 15-06-1998 |
| | | | JP 7188065 A | 25-07-1995 |
| | | | NO 943825 A | 18-04-1995 |
| | | | NZ 264633 A | 22-09-1997 |
| | | | PL 305326 A1 | 18-04-1995 |
| | | | PT 650965 T | 31-05-2001 |
| | | | RU 2127269 C1 | 10-03-1999 |
| | | | SI 650965 T1 | 30-06-2001 |
| | | | TW 381090 B | 01-02-2000 |
| | | | US 5491243 A | 13-02-1996 |
| | | | ZA 9407839 A | 09-04-1996 |
| US 3855227 | A | 17-12-1974 | US 3912761 A | 14-10-1975 |
| | | | US 3904632 A | 09-09-1975 |
| US 4036852 | A | 19-07-1977 | NL 7413843 A | 27-04-1976 |
| | | | DE 2547548 A1 | 29-04-1976 |
| | | | GB 1469616 A | 06-04-1977 |
| | | | JP 51080838 A | 15-07-1976 |
| US 5023569 | A | 11-06-1991 | NONE | |